Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
posted on
Dec 22, 2020 08:45AM
To your point, the referenced publication is dated December 11, 2020.
As for withholding information considered material, it is my opinion that this news is not material. It is when something is proven, i.e. Phase 3 trial results, that it meets the definition of material. JMHO